Short-Term Debt to Equity Ratio: PepGen (PEPG)
Developing muscular dystrophy drugs requires colossal R&D expenditures, which keeps operating profit low, while international conflicts complicate patent protection and the procurement of rare reagents. The price trend featuring the 0.03 metric clearly demonstrates the dynamics of PepGen Inc. (PEPG). The business's success relies on a team of elite biochemists, who are attracted by generous bonuses and the freedom to conduct scientific research.
PepGen Corp - analytical breakdowns and key metrics (PEPG)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
- company profitability and valuation multiples indicators:
Analysis of all company metrics:PEPG PepGen
This indicator assesses financial stability via the share of short-term borrowings within the equity structure, signaling the degree of the business's dependence on rapid refinancing. By analyzing the shifting ratio of current liabilities to equity, an investor can discern the liquidity risk of PepGen Inc. (PEPG), whose valuation is based solely on patent prospects in the complete absence of current revenue from commercial products.
Competitor analysis for PepGen Inc.
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|denalitherapeutics.com - Current Liabilities to Equity|Short-Term Debt to Capital HRMY|BHVN - Current Liabilities to Capital|Short-Term Debt to Equity Amylyx AMLX|TRVI (Trevi Corp) - Current Liabilities to Equity|Praxis Precision Medicines - Short-Term Debt to Capital|Short-Term Indebtedness to Equity anavex.com (AVXL)|CBLL: Short-Term Debt to Capital|Current Liabilities to Capital Prothena Biosciences (PRTA)|Short-Term Debt to Equity Alector Inc.|Short-Term Debt to Capital Ratio ANNX (Annexon Biosciences Inc.)|Short-Term Debt to Equity Ratio OMER (Omeros Corporation)|NGNE (neurogene.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ACIU (AC Immune SA)|Short-Term Debt to Capital Coefficient Voyager Therapeutics Inc (VYGR)|NMRA - Short-Term Debt to Equity|SCLX (Scilex Holding Company, Inc.) - Short-Term Debt to Capital Ratio|TVGN: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Alpha Cognition Inc.|Short-Term Debt to Equity Ratio CGTX|Inhibikase Therapeutics Inc (IKT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Cassava (SAVA)|ASRT: Current Liabilities to Equity|Short-Term Debt to Capital COYA (Coya Therapeutics)|VistaGen Therapeutics, Inc. (VTGN) - Current Liabilities to Capital|OVID - Short-Term Debt to Equity|Current Liabilities to Equity ABOS|CRVO: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Alterity Therapeutics Limited ATHE|Short-Term Debt to Equity Clene Inc|Short-Term Debt to Capital Ratio JUNS (jupiterneurosciences.com)|Short-Term Debt to Capital RLMD|ANVS - Current Liabilities to Capital|Grace Therapeutics - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Firefly Neuro AIFF|KLTO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital NRSN (NeuroSense Therapeutics)|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Short-Term Debt to Equity|Current Liabilities to Capital MetaVia (MTVA)|Short-Term Debt to Equity NeurAxis, Inc|Helius Medical Technologies Inc. - Current Liabilities to Equity|Short-Term Debt to Capital PASG|NEUP - Current Liabilities to Capital|Short-Term Debt to Equity Minerva Neurosciences, Inc. NERV|ATHA (Athira Pharma Inc) - Current Liabilities to Equity|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity Alzamend Neuro, Inc. (ALZN)|CYCN: Short-Term Debt to Capital|Current Liabilities to Capital Protagenic Therapeutics, Inc. (PTIX)|Short-Term Debt to Equity Pasithea Therapeutics Corp|Short-Term Debt to Capital Ratio CRGT (Cortigent Medical)|Short-Term Debt to Equity Ratio ATXI (Avenue Therapeutics, Inc)|BCLI (BrainStorm Cell Therapeutics Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CARA (Cara Therapeutics, Inc.)|Short-Term Debt to Capital Coefficient chromocell.com (CHRO)|ELYM - Short-Term Debt to Equity|ITCI (Intra-Cellular Therapies) - Short-Term Debt to Capital Ratio|LBPH: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Marinus Pharma|Short-Term Debt to Equity Ratio NKGN|neurobopharma.com (NRBO) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Sage Therapeutics (SAGE)|SNPX: Current Liabilities to Equity|Short-Term Debt to Capital TRVN (Trevena, Inc)|Vigil Neuroscience Inc. (VIGL) - Current Liabilities to Capital|WENA - Short-Term Debt to Equity|Current Liabilities to Equity CERE